Literature DB >> 18528631

A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity.

Göran Starck1, Maria Ljungberg, Marie Nilsson, Lars Jönsson, Stefan Lundberg, Tord Ivarsson, Susanne Ribbelin, Sven Ekholm, Arvid Carlsson, Eva Forssell-Aronsson, Maria L Carlsson.   

Abstract

1H magnetic resonance spectroscopy (1H MRS) studies exploring brain metabolites, especially glutamine + glutamate (Glx), in obsessive compulsive disorder (OCD) are of vital interest for trying to understand more about the pathophysiology of OCD. Therefore, we conducted the present 1H MRS study with the aims of (1) comparing MRS metabolites in a group of adult patients with OCD and a group of healthy controls, and (2) examining the relationship between MRS metabolite concentrations and symptom severity in the patient group. Three brain regions were studied, the right caudate nucleus, the anterior gyrus cinguli and the occipital cortex bilaterally. Since multivariate analysis is a highly useful tool for extraction of 1H MRS data, we applied principal component analysis (PCA) and partial least square projection to latent structures (PLS) to the MRS data. PLS disclosed a strong relationship between several of the metabolites and OCD symptom severity, as measured with Yale-Brown obsessive-compulsive scale (YBOCS): the YBOCS score was found to be positively correlated to caudate creatine, Glx, glutamate, and choline compounds as well as occipital cortex myoinositol, and negatively correlated to occipital cortex Glx. The negative correlation between occipital cortex Glx and YBOCS was the most impressive. PCA did not reveal any tendency for a separation between the patients with OCD and controls with respect to MRS metabolites. The results are discussed in relation to corticostriatothalamocortical feedback and previous observations of poor visuospatial ability in OCD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528631     DOI: 10.1007/s00702-008-0045-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  36 in total

Review 1.  The thalamic reticular nucleus: structure, function and concept.

Authors:  Didier Pinault
Journal:  Brain Res Brain Res Rev       Date:  2004-08

2.  Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder.

Authors:  S E Swedo; M B Schapiro; C L Grady; D L Cheslow; H L Leonard; A Kumar; R Friedland; S I Rapoport; J L Rapoport
Journal:  Arch Gen Psychiatry       Date:  1989-06

3.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine.

Authors:  C Benkelfat; T E Nordahl; W E Semple; A C King; D L Murphy; R M Cohen
Journal:  Arch Gen Psychiatry       Date:  1990-09

4.  Regional 133xenon cerebral blood flow and cerebral 99mTc-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment.

Authors:  R T Rubin; J Ananth; J Villanueva-Meyer; P G Trajmar; I Mena
Journal:  Biol Psychiatry       Date:  1995-10-01       Impact factor: 13.382

5.  Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder.

Authors:  Jun Soo Kwon; Jae-Jin Kim; Dong Woo Lee; Jae Sung Lee; Dong Soo Lee; Myung-Sun Kim; In Kyoon Lyoo; Maeng Je Cho; Myung Chul Lee
Journal:  Psychiatry Res       Date:  2003-01-20       Impact factor: 3.222

6.  Cerebral glucose metabolic rates in obsessive compulsive disorder.

Authors:  T E Nordahl; C Benkelfat; W E Semple; M Gross; A C King; R M Cohen
Journal:  Neuropsychopharmacology       Date:  1989-03       Impact factor: 7.853

7.  Neuropsychological performance and regional cerebral blood flow in obsessive-compulsive disorder.

Authors:  Acioly L T Lacerda; Paulo Dalgalarrondo; Dorgival Caetano; Gretchen L Haas; Edwaldo E Camargo; Matcheri S Keshavan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-06       Impact factor: 5.067

Review 8.  In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function.

Authors:  Douglas L Rothman; Kevin L Behar; Fahmeed Hyder; Robert G Shulman
Journal:  Annu Rev Physiol       Date:  2002-05-01       Impact factor: 19.318

9.  On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression.

Authors:  L O Hansson; N Waters; S Holm; C Sonesson
Journal:  J Med Chem       Date:  1995-08-04       Impact factor: 7.446

10.  A meta-analysis of functional neuroimaging in obsessive-compulsive disorder.

Authors:  Stephen P Whiteside; John D Port; Jonathan S Abramowitz
Journal:  Psychiatry Res       Date:  2004-11-15       Impact factor: 3.222

View more
  32 in total

1.  Degraded water suppression in small volume ¹H MRS due to localised shimming.

Authors:  Asa Carlsson; Maria Ljungberg; Göran Starck; Eva Forssell-Aronsson
Journal:  MAGMA       Date:  2011-01-06       Impact factor: 2.310

2.  Structural changes in the gray matter of unmedicated patients with obsessive-compulsive disorder: a voxel-based morphometric study.

Authors:  Ling Tan; Qing Fan; Chao You; Jijun Wang; Zhao Dong; Xuemei Wang; Kemin Chen; Zeping Xiao; Kaida Jiang
Journal:  Neurosci Bull       Date:  2013-08-28       Impact factor: 5.203

3.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

4.  An Examination of Rostral Anterior Cingulate Cortex Function and Neurochemistry in Obsessive-Compulsive Disorder.

Authors:  Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch
Journal:  Neuropsychopharmacology       Date:  2015-02-09       Impact factor: 7.853

5.  Relevance of orbitofrontal neurochemistry for the outcome of cognitive-behavioural therapy in patients with obsessive-compulsive disorder.

Authors:  Bartosz Zurowski; Andreas Kordon; Wolfgang Weber-Fahr; Ulrich Voderholzer; Anne Katrin Kuelz; Tobias Freyer; Karina Wahl; Christian Büchel; Fritz Hohagen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

6.  OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior.

Authors:  Isaac D Zike; Muhammad O Chohan; Jared M Kopelman; Emily N Krasnow; Daniel Flicker; Katherine M Nautiyal; Michael Bubser; Christoph Kellendonk; Carrie K Jones; Gregg Stanwood; Kenji Fransis Tanaka; Holly Moore; Susanne E Ahmari; Jeremy Veenstra-VanderWeele
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

7.  Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies.

Authors:  Shibany P Taormina; Matthew P Galloway; David R Rosenberg
Journal:  J Dev Behav Pediatr       Date:  2016 Jul-Aug       Impact factor: 2.225

Review 8.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

9.  In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; R Todd Ogden; Xiangling Mao; Matthew S Milak; Donna Vermes; Shan Xie; Liane Hunter; Pamela Flood; Holly Moore; Dikoma C Shungu; Helen B Simpson
Journal:  Psychiatry Res       Date:  2015-06-06       Impact factor: 3.222

10.  In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors:  Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.